biostudies-literatureUnknown10Cloß Kinternal grant program of the University Hospital Aachen, RWTH Aachen University, GermanyDeutsche Forschungsgemeinschaft<h4>Objective</h4>This review aims to systematically map and categorize the current state of wearable applications among oncology patients and to identify determinants impeding clinical implementation.<h4>Methods</h4>A Medline, Embase and clinicaltrials.gov search identified journal articles, conference abstracts, letters, reports, dissertations and registered studies on the use of wearables in patients with malignancies published up to 10 November 2021.<h4>Results</h4>Of 2509 records identified, 112 met the eligibility criteria. Of these, 9.8% (11/112) were RCTs and 47.3% (53/112) of publications were observational. Wearables were investigated pre-treatment (2.7%; 3/112), during treatment (34.8%; 39/112), post-treatment (17.9%; 20/112), in survivors (27.7%; 31/112) and in non-specified orDigital health20552076241233998https://www.ebi.ac.uk/biostudies/studies/S-EPMC10933580biostudies-literatureApplication of wearables for remote monitoring of oncology patients: A scoping review.PMC10933580Verket MBeier FJost ECrysandt MBrandts JMuller-Wieland DJacobsen MCloß KKobbe GMarx NSchuett KBrummendorf THfalseApplication of wearables for remote monitoring of oncology patients: A scoping review.<h4>Objective</h4>This review aims to systematically map and categorize the current state of wearable applications among oncology patients and to identify determinants impeding clinical implementation.<h4>Methods</h4>A Medline, Embase and clinicaltrials.gov search identified journal articles, conference abstracts, letters, reports, dissertations and registered studies on the use of wearables in patients with malignancies published up to 10 November 2021.<h4>Results</h4>Of 2509 records identified, 112 met the eligibility criteria. Of these, 9.8% (11/112) were RCTs and 47.3% (53/112) of publications were observational. Wearables were investigated pre-treatment (2.7%; 3/112), during treatment (34.8%; 39/112), post-treatment (17.9%; 20/112), in survivors (27.7%; 31/112) and in non-specified or2024-01-01T00:00:00Z2024 Jan-Dec2026-07-15T04:20:10.514Z2026-06-29T03:08:27.547ZS-EPMC109335803848179610.1177/20552076241233998